Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and Akt

BACKGROUND AND PURPOSE: Regression of left ventricular hypertrophy by moxonidine, a centrally acting sympatholytic imidazoline compound, results from a sustained reduction of DNA synthesis and transient stimulation of DNA fragmentation. Because apoptosis of cardiomyocytes may lead to contractile dys...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Aceros, H, Farah, G, Cobos-Puc, L, Stabile, AM, Noiseux, N, Mukaddam-Daher, S
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2011
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3195917/
https://ncbi.nlm.nih.gov/pubmed/21426316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2011.01355.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados